Sandra M Swain

Sandra M Swain

UNVERIFIED PROFILE

Are you Sandra M Swain?   Register this Author

Register author
Sandra M Swain

Sandra M Swain

Publications by authors named "Sandra M Swain"

Are you Sandra M Swain?   Register this Author

100Publications

2537Reads

19Profile Views

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.

Breast Cancer Res Treat 2019 Nov 19;178(2):389-399. Epub 2019 Aug 19.

National Surgical Adjuvant Breast and Bowel Project (NSABP), Nova Tower 2, 100 Allegheny Square, Pittsburgh, PA, 15212, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05398-3DOI Listing
November 2019

CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities.

Pharmacol Ther 2018 11 19;191:65-73. Epub 2018 Jun 19.

Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2018.06.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533626PMC
November 2018

Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low?

JACC Cardiovasc Imaging 2018 08;11(8):1094-1097

Division of Medical Oncology, Department of Medicine, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S1936878X183052
Publisher Site
http://dx.doi.org/10.1016/j.jcmg.2018.02.027DOI Listing
August 2018

Luminal A Breast Cancer and Molecular Assays: A Review.

Oncologist 2018 05 22;23(5):556-565. Epub 2018 Feb 22.

Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C., USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947456PMC
May 2018

Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.

J Natl Cancer Inst 2018 02;110(2)

NRG Oncology and The University of Pittsburgh, Pittsburgh, PA; Center for Healthcare Policy and Research, University of California Davis, Sacramento, CA; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; NRG Oncology and The Washington Cancer Institute at Washington Hospital Center, Washington, DC and current: Georgetown University, Washington, DC; NRG Oncology and The Colorado Cancer Research Program, Denver, CO; NRG Oncology and Kaiser Permanente, Northern California, Vallejo, CA; NRG Oncology and The Central Illinois CCOP Heartland NCORP, Decatur, IL; NRG Oncology and The University of Pittsburgh/Magee Womens Hospital, Pittsburgh, PA; NRG Oncology and The Allegheny Health Network, Pittsburgh, PA; NRG Oncology and The Jewish General Hospital, McGill University, Montréal, QC, Canada; NRG Oncology and The MedStar Franklin Square Medical Center/Harry and Jeanette Weinberg Cancer Institute, Baltimore, MD; NRG Oncology and The University of California Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA; Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5825682PMC
February 2018

Take care of your neighborhood.

Breast Cancer Res Treat 2018 01 12;167(1):225-234. Epub 2017 Sep 12.

Washington Cancer Institute, MedStar Washington Hospital Center, 110 Irving Street NW, Washington, DC, 20010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4492-1DOI Listing
January 2018

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.

J Clin Oncol 2017 Dec 26;35(35):3942-3948. Epub 2017 Oct 26.

All authors: National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Reena S. Cecchini, Priya Rastogi, Jong-Hyeon Jeong, and Adam M. Brufsky, University of Pittsburgh; Priya Rastogi and Adam M. Brufsky, Magee-Womens Hospital; Norman Wolmark, Allegheny Health Network Cancer Institute, Pittsburgh, PA; Patricia A. Ganz, University of California at Los Angeles, Los Angeles; Louis Fehrenbacher, Kaiser Permanente, Vallejo; Jonathan Polikoff, Kaiser Permanente, San Marco, CA; Edward H. Romond, University of Kentucky, Lexington, KY; Charles E. Geyer Jr, Virginia Commonwealth University, Richmond, VA; Sandra M. Swain and John L. Zapas, MedStar Washington Hospital Center, Washington, DC; Howard M. Gross, Dayton National Cancer Institute Community Oncology Research Program (NCORP), Dayton, OH; Patrick J. Flynn, Metro-Minnesota Community Clinical Oncology Program (CCOP), Woodbury, MN; Tanya A. Wahl, Fred Hutchinson Cancer Research Center, Seattle, WA; Thomas E. Seay, Atlanta Regional CCOP, Atlanta, GA; James L. Wade III, Heartland NCORP, Decatur, IL; David D. Biggs, Christiana Care Health System, Newark, DE; James N. Atkins, Southeast Clinical Oncology Research Consortium NCORP, Goldsboro, NC; and Eleftherios P. Mamounas, Orlando Health, Orlando, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.1165DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721228PMC
December 2017

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

J Clin Oncol 2017 Aug 11;35(23):2647-2655. Epub 2017 Apr 11.

Joanne L. Blum, Lina Asmar, Nicholas J. Robert, Joyce A. O'Shaughnessy, Svetislava J. Vukelja, Devchand Paul, and Stephen E. Jones, US Oncology Research; Lina Asmar, McKesson Specialty Health, The Woodlands; Joanne L. Blum and Joyce A. O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas; Svetislava J. Vukelja, Texas Oncology-Tyler, Tyler, TX; Patrick J. Flynn, Charles E. Geyer Jr, Samuel A. Jacobs, Judith O. Hopkins, Louis Fehrenbacher, Alan P. Lyss, Adam M. Brufsky, Sandra M. Swain, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project/NRG Oncology; Greg Yothers, Jong-Hyeon Jeong, and Linda H. Colangelo, NRG Oncology; Greg Yothers, John-Hyeon Jeong, and Linda H. Colangelo, The University of Pittsburgh; Samuel A. Jacobs, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine; Adam M. Brufsky, Magee-Womens Hospital at University of Pittsburgh Medical Center; Norman Wolmark, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh; Henry Leonidas Gómez, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA; Patrick J. Flynn, Metro-Minnesota Community Oncology Research Consortium, Minneapolis, MN; Charles E. Geyer Jr, Massey Cancer Center, Virginia Commonwealth University, Richmond; Nicholas J. Robert, Virginia Cancer Specialists, Fairfax, VA; Judith O. Hopkins, The Southeastern Medical Oncology Center, Goldsboro, NC; Chau T. Dang, The Alliance, Boston, MA; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York, NY; Henry Leonidas Gómez, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Louis Fehrenbacher, Kaiser Permanente Oncology Clinical Trials Northern California, Vallejo, CA; Alan P. Liss, Heartland Cancer Research National Cancer Institute Community Oncology Research Program at Missouri Baptist Cancer Center, St Louis, MO; Devchand Paul, Rocky Mountain Cancer Centers, Denver, CO; Sandra M. Swain, MedStar Washington Hospital Center Washington Cancer Institute, and Georgetown University Medical Center, Washington, DC; and Eleftherios P. Mamounas, UF Cancer Center at Orlando Health, Orlando, FL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.4147
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.4147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549453PMC
August 2017

HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.

Clin Breast Cancer 2017 02 27;17(1):76-78. Epub 2016 Aug 27.

Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2016.08.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896289PMC
February 2017

Focus on You: Cancer clinical trials perspectives.

Contemp Clin Trials Commun 2016 Dec 16;4:170-178. Epub 2016 Sep 16.

Washington Cancer Institute at MedStar Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.conctc.2016.09.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536902PMC
December 2016

Genomic profiling of breast cancer in African-American women using MammaPrint.

Breast Cancer Res Treat 2016 Oct 27;159(3):481-8. Epub 2016 Aug 27.

Georgetown University Medical Center, 4000 Reservoir Road NW, 120 Building B, Washington, DC, 20057-1400, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3949-yDOI Listing
October 2016

Cardiac Protection in HER2-Targeted Treatment: How Should We Measure New Strategies?

JAMA Oncol 2016 08;2(8):1037-9

Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.0283DOI Listing
August 2016

Pertuzumab for the treatment of breast cancer: a safety review.

Expert Opin Drug Saf 2016 Jun 12;15(6):853-63. Epub 2016 Apr 12.

b Washington Cancer Institute, MedStar Washington Hospital Center , Washington , DC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2016.1167185DOI Listing
June 2016

A critical review of the enrollment of black patients in cancer clinical trials.

Am Soc Clin Oncol Educ Book 2012 :153-7

From the Washington Cancer Institute at Medstar Washington Hospital Center, Washington, DC; Medstar Health Research Institute, Hyattsville, MD; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD; Johns Hopkins Center to Reduce Cancer Disparities, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.153DOI Listing
April 2016

Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?

Oncologist 2016 Apr 16;21(4):399-401. Epub 2016 Mar 16.

The Washington Cancer Institute, Washington, D.C., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828130PMC
April 2016

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Breast Cancer Res Treat 2016 Jan 12;155(2):235-51. Epub 2016 Jan 12.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 4B54, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3673-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753803PMC
January 2016

Quantitative Gene Expression by Recurrence Score in ER-Positive Breast Cancer, by Age.

Adv Ther 2015 Dec 26;32(12):1222-36. Epub 2015 Nov 26.

Genomic Health, Inc., Redwood City, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-015-0268-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679789PMC
December 2015

Reply to a. Avan et Al.

J Clin Oncol 2015 May 13;33(15):1712. Epub 2015 Apr 13.

Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8398DOI Listing
May 2015

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

J Clin Oncol 2015 Apr 5;33(12):1340-7. Epub 2015 Jan 5.

Katherine L. Pogue-Geile, Nan Song, Patrick G. Gavin, Seong-Rim Kim, Nicole L. Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Sandra M. Swain, D. Lawrence Wickerham, Charles E. Geyer Jr, Norman Wolmark, and Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project (now part of NRG Oncology); Jong-Hyeon Jeong and Joseph P. Costantino, NRG Oncology Statistics and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA; and Soonmyung Paik, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/12/1340.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.56.2439
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.2439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397278PMC
April 2015

Improving Documentation of Pain Management at MedStar Washington Cancer Institute.

J Oncol Pract 2015 Mar 17;11(2):155-7. Epub 2015 Feb 17.

MedStar Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2014.001636DOI Listing
March 2015

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

J Clin Oncol 2014 Nov 20;32(33):3753-61. Epub 2014 Oct 20.

José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Javier Cortés, Vall d'Hebron University Hospital, Barcelona, Spain; Seock-Ah Im, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; Emma Clark and Graham Ross, Roche Products, Welwyn Garden City, United Kingdom; Astrid Kiermaier, F. Hoffmann-La Roche, Basel, Switzerland; and Sandra M. Swain, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.54.5384
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.5384DOI Listing
November 2014

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

J Clin Oncol 2014 Nov 20;32(33):3744-52. Epub 2014 Oct 20.

Edith A. Perez, Gerardo Colon-Otero, the Mayo Clinic, Jacksonville; Eleftherios Mamounas, University of Florida Health Cancer Center-Orlando Health, Orlando, FL; Edward H. Romond, University of Kentucky, Lexington, KY; Vera J. Suman, Mayo Clinic, Rochester, MN; Jong-Hyeon Jeong, Priya Rastogi, University of Pittsburgh; Nancy E. Davidson, University of Pittsburgh Cancer Institute; Norman Wolmark, Allegheny General Hospital, Pittsburgh, PA; George Sledge, Stanford University School of Medicine, Stanford; Silvana Martino, The Angeles Clinic and Research Institute, Santa Monica, CA; Charles E. Geyer Jr, Virginia Commonwealth University Massey Cancer Center, Richmond, VA; Julie Gralow, University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Sandra M. Swain, MedStar Washington Hospital Center, Washington, DC; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jo Anne Zujewski, National Institutes of Health, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.5730DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805PMC
November 2014

Pertuzumab for the treatment of breast cancer.

Cancer Invest 2014 Oct 12;32(8):430-8. Epub 2014 Jun 12.

Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/07357907.2014.922570DOI Listing
October 2014

Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

Oncologist 2014 Jul 28;19(7):693-701. Epub 2014 May 28.

Washington Cancer Institute, MedStar Washington Hospital Center, Washington, D.C., USA; Division of Hematology and Medical Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Division of Hematology and Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Veterans Memorial Medical Center, Cancer Research Center, Quezon City, Philippines; Mount Vernon Cancer Centre, Middlesex, United Kingdom; Roche Products Ltd., Welwyn Garden City, United Kingdom; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, New York, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/lookup/doi/10.1634/th
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2014-0033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077449PMC
July 2014

Pertuzumab: increasing the options.

Oncology (Williston Park) 2014 Mar;28(3):199, 204, 210

View Article

Download full-text PDF

Source
March 2014

Reply to E.J. Moylan et al.

J Clin Oncol 2014 Feb 13;32(6):606-7. Epub 2014 Jan 13.

National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; and Medstar Washington Hospital Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.8744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918541PMC
February 2014

Adjuvant trastuzumab: does time really matter?

Authors:
Sandra M Swain

Oncologist 2013 26;18(5):490-2. Epub 2013 Apr 26.

Washington Cancer Institute, MedStar Washington Hospital Center, Washington, District of Columbia 20010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3662838PMC
December 2013

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

J Natl Cancer Inst 2013 Dec 21;105(23):1782-8. Epub 2013 Nov 21.

Affiliations of authors: National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA (J-HJ, HB, PR, LF, EHR, SMS, EPM, DLW, CEG,Jr, JPC, NW, SP); Division of Pathology, NSABP (KLP-G, CK, NT, PGG, DF, YT, OLB, AL, S-IK, MLR, MYR, NLB, S-RK, ZDH); Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (J-HJ, HB, JPC); PhenoPath Laboratories, PLLC, Seattle, WA (LCG); Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX (NS); Department of Pathology, University Medical Center Hamburg-Eppendorf, University Cancer Center, Hamburg, Germany (EB); Department of Pathology, Catholic University of Korea, Seoul, Republic of South Korea (AL); University of Pittsburgh Cancer Institute, Pittsburgh, PA (PR); Department of Oncology, Kaiser Permanente, Northern California, Vallejo, CA (LF); Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY (EHR); Department of Medicine, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC (SMS); Department of Surgery, MD Anderson Cancer Center Orlando, Orlando, FL (EPM); Department of Medicine, Virginia Commonwealth University, Richmond, VA (CEG, Jr); Department of Surgery, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA (DLW, NW); Department of Biomedical Science, Severance Biomedical Science Institute, and Department of Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea (SP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848987PMC
December 2013

Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel.

Anticancer Drugs 2013 Nov;24(10):1084-92

aVall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain bMedStar Washington Hospital Center, Washington Cancer Institute, Washington, District of Columbia cMid Ohio Oncology/Hematology Inc., The Mark H. Zangmeister Center, Columbus, Ohio dGenentech, South San Francisco, California eMemorial Sloan-Kettering Cancer Center, New York, New York, USA fRiga East University Hospital Oncology Center, Riga, Latvia gDaugavpils Reǵionālā Slimnīca, Daugavpils, Latvia hGesundheitszentrum Fricktal, Spital Rheinfelden & Laufenburg, Rheinfelden, Switzerland iNational Hospital Organization Osaka National Hospital, Osaka-City, Osaka, Japan jRoche Products Limited, Welwyn Garden City, UK kPharsight, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000016DOI Listing
November 2013

NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors.

Evid Based Complement Alternat Med 2013 27;2013:964592. Epub 2013 Oct 27.

The Cancer Team at Bellin Health, 1580 Commanche Avenue, Green Bay, WI 54313, USA ; National Center for Complementary and Alternative Medicine, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/964592DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826324PMC
November 2013

Building bridges to conquer cancer.

Authors:
Sandra M Swain

J Clin Oncol 2013 Oct 16;31(30):3731-6. Epub 2013 Sep 16.

From the Medstar Washington Hospital Center, Washington Cancer Institute, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.6202DOI Listing
October 2013

Drug discount program.

JAMA 2013 Oct;310(15):1626-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2013.276737DOI Listing
October 2013

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

J Clin Oncol 2013 Sep 12;31(26):3197-204. Epub 2013 Aug 12.

Sandra M. Swain, Gong Tang, Charles E. Geyer Jr, Priya Rastogi, James N. Atkins, Paul P. Donnellan, Louis Fehrenbacher, Catherine A. Azar, André Robidoux, Jonathan A. Polikoff, Adam M. Brufsky, David D. Biggs, Edward A. Levine, John L. Zapas, Louise Provencher, Soonmyung Paik, Joseph P. Costantino, Eleftherios P. Mamounas, and Norman Wolmark, National Surgical Adjuvant Breast and Bowel Project (NSABP); Norman Wolmark, Allegheny General Hospital, Allegheny Health Network; Gong Tang and Joseph P. Costantino, NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health; Priya Rastogi, University of Pittsburgh Cancer Institute; Adam M. Brufsky, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra M. Swain, MedStar Washington Hospital Center, Washington, DC; Charles E. Geyer Jr, Virginia Commonwealth University, Richmond, VA; James N. Atkins, Southeast Cancer Control Consortium-Community Clinical Oncology Program, Goldsboro; Edward A. Levine, Wake Forest University, Winston-Salem, NC; Paul P. Donnellan, University Hospital, Galway, and the All-Ireland Cooperative Oncology Research Group, Dublin, Ireland; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo; Jonathan A. Polikoff, Kaiser Permanente Southern California, San Diego, CA; Catherine A. Azar, Kaiser Permanente, Denver, CO; André Robidoux, Centre hopitalier de l'Université de Montréal (CHUM), Montréal; Louise Provencher, CHU de Québec, Hôpital du Saint-Sacrement, Québec City, QC, Canada; David D. Biggs, Helen F. Graham Cancer Center, Christiana Care Health System, Newark, DE; John L. Zapas, Medstar Franklin Square Medical Center, Baltimore, MD; Donald W. Northfelt, Mayo Clinic Arizona, Scottsdale, AZ; and Eleftherios P. Mamounas, MD Anderson Cancer Center, Orlando, FL.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2013/08/12/JCO.2012.48
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.48.1275
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.48.1275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757290PMC
September 2013

Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.

Expert Opin Biol Ther 2013 May 27;13(5):779-90. Epub 2013 Mar 27.

Medical Oncology Branch, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2013.783007DOI Listing
May 2013

Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia.

Cancer Med 2013 Apr 24;2(2):178-84. Epub 2013 Jan 24.

Division of Cancer Epidemiology and Genetics, National Cancer, Institute 6120 Executive Blvd., Rockville, Maryland, 20852-7234, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.48DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639656PMC
April 2013

Insights from the cancer center business summit: preparing for the future. Foreword.

Authors:
Sandra M Swain

J Oncol Pract 2013 Mar;9(2):69

Medstar Washington Hospital Center’s Washington Cancer Institute, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2013.000917DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595438PMC
March 2013

Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS metastases: the Road less Travelled.

Curr Mol Pharmacol 2013 Jan 8. Epub 2013 Jan 8.

Washington Cancer Institute Washington Hospital Center Washington, DC, USA.

View Article

Download full-text PDF

Source
January 2013

Treatment and cost implications of pertuzumab.

Am J Manag Care 2012 Sep;18(4 Spec No.):SP151-3

View Article

Download full-text PDF

Source
September 2012

Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.

Clin Breast Cancer 2012 Aug 12;12(4):232-9. Epub 2012 Jun 12.

George Washington University School of Public Health and Health Services, Washington, DC 20037, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2012.04.005DOI Listing
August 2012

Twenty-five year results of the national cancer institute randomized breast conservation trial.

Breast Cancer Res Treat 2012 Feb 24;132(1):197-203. Epub 2011 Nov 24.

Radiation Oncology Branch, National Cancer Institute/NIH, Building 10-CRC, Room B2-3500, 10 Center Drive, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1867-6DOI Listing
February 2012

Pazopanib for the treatment of breast cancer.

Expert Opin Investig Drugs 2012 Feb 10;21(2):217-25. Epub 2012 Jan 10.

National Cancer Institute, 10 Center Drive, 12N226, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/13543784.2012.65
Publisher Site
http://dx.doi.org/10.1517/13543784.2012.652304DOI Listing
February 2012

Avastin withdrawal symptoms.

Expert Opin Pharmacother 2012 Feb 21;13(3):293-8. Epub 2012 Jan 21.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14656566.2012.65
Publisher Site
http://dx.doi.org/10.1517/14656566.2012.652088DOI Listing
February 2012

Cardiac dysfunction after cancer treatment.

Tex Heart Inst J 2011 ;38(3):248-52

Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113132PMC
October 2011

Chemotherapy: updates and new perspectives.

Authors:
Sandra M Swain

Oncologist 2011 ;16 Suppl 1:30-9

Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2011-S1-30DOI Listing
June 2011

p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.

Int J Oncol 2011 May 9;38(5):1445-52. Epub 2011 Mar 9.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bldg. 37/Rm 1048, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2011.966DOI Listing
May 2011

Chemotherapy: updates and new perspectives.

Authors:
Sandra M Swain

Oncologist 2010 ;15 Suppl 5:8-17

Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2010-S5-08DOI Listing
March 2011

The impact of systemic therapy following ductal carcinoma in situ.

J Natl Cancer Inst Monogr 2010 ;2010(41):200-3

Department of Internal Medicine, Division of Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgq021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999067PMC
February 2011

Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?

J Clin Oncol 2011 Feb 4;29(6):603-6. Epub 2011 Jan 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.32.9060DOI Listing
February 2011

Meta-analysis: should it be more than the sum of its parts?

J Natl Cancer Inst 2010 Dec 23;102(24):1817-9. Epub 2010 Nov 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djq469DOI Listing
December 2010

Amenorrhea from breast cancer therapy--not a matter of dose.

N Engl J Med 2010 Dec;363(23):2268-70

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1009616DOI Listing
December 2010

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.

Clin Breast Cancer 2010 Dec;10(6):489-91

Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2010.n.065DOI Listing
December 2010

Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.

J Clin Oncol 2010 Jun 17;28(18):2974-81. Epub 2010 May 17.

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.26.1602
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.26.1602DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903333PMC
June 2010

Primary systemic chemotherapy for inflammatory breast cancer.

Cancer 2010 Jun;116(11 Suppl):2821-8

Department of Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25166DOI Listing
June 2010

Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.

Breast Cancer Res Treat 2010 Feb;119(3):685-99

Division of Medical Oncology, Department of Medicine University of Washington/Seattle Cancer Care Alliance, G3639, 825 Eastlake Ave, E, Seattle, WA 98109, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-009-0651-3
Publisher Site
http://dx.doi.org/10.1007/s10549-009-0651-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892182PMC
February 2010

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Nat Rev Cancer 2009 Jul 18;9(7):463-75. Epub 2009 Jun 18.

Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrc2656
Publisher Site
http://dx.doi.org/10.1038/nrc2656DOI Listing
July 2009

The influence of a gene expression profile on breast cancer decisions.

J Surg Oncol 2009 May;99(6):319-23

Division of Surgical Oncology, Department of Surgery, National Naval Medical Center, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.21244DOI Listing
May 2009

Therapeutic strategies for triple-negative breast cancer.

Cancer J 2008 Nov-Dec;14(6):343-51

The Cancer Institute of New Jersey, New Brunswick, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31818d839bDOI Listing
February 2009

First, do no harm.

Onkologie 2008 Oct 23;31(10):511-2. Epub 2008 Sep 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000154472DOI Listing
October 2008

Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer.

Clin Cancer Res 2008 Sep;14(18):5893-9

National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-4762DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2587275PMC
September 2008

Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.

Clin Adv Hematol Oncol 2008 Jun;6(6):455-67

Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA.

View Article

Download full-text PDF

Source
June 2008

Cardiovascular complications of breast cancer therapy.

Authors:
Sandra M Swain

Clin Adv Hematol Oncol 2008 Apr;6(4):247-8, 282

Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA.

View Article

Download full-text PDF

Source
April 2008

Ixabepilone for the treatment of solid tumors: a review of clinical data.

Expert Opin Investig Drugs 2008 Mar;17(3):423-35

National Cancer Institute, National Institutes of Health, Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, 10 Center Drive, Room 12N226, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.17.3.423DOI Listing
March 2008

The epothilones: translating from the laboratory to the clinic.

Clin Cancer Res 2008 Mar;14(6):1618-24

Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-2201DOI Listing
March 2008